Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 9, Issue 3, Pages 355-368Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590902763755
Keywords
antibody; Hendra virus; Nipah virus; SARS CoV; therapeutics; vaccines
Funding
- National Institutes of Health (NIH)
- Middle Atlantic Regional Center of Excellence (MARCE) [AI057168]
- Uniformed Services University of the Health Sciences (USUHS) [R0731L]
- Intramural Research Program of the NIH
- National Cancer Institute
- Center for Cancer Research
- National Institutes of Health [NOI-CO-12400]
- NATIONAL CANCER INSTITUTE [ZIABC011156] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057168] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Background: Recently, several potent human monoclonal antibodies (hmAbs) targeting the severe acute respiratory syndrome-associated coronavirus (SARS CoV) S glycoproteins, as well as the first fully human mAbs against two other paramyxoviruses, Hendra virus (HeV) and Nipah virus (NiV) have been discovered. Objective: To examine, compare and contrast the functional characteristics of hmAbs with potential for prophylaxis and treatment of diseases caused by SARS CoV, HeV and NiV. Methods: A review of relevant literature. Results/conclusions: Structural analyses have provided insights into the molecular mechanisms of receptor recognition and antibody neutralization, and suggested that these antibodies alone or in combination could fight the viruses' heterogeneity and mutability, which is a major problem in the development of effective therapeutic agents against viruses, including therapeutic antibodies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available